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Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of a
derivative chromosome 22 [der(22)] commonly called Philadelphia chromosome (Ph). The Ph chromosome is a
product of the reciprocal translocation t(9;22)(q34.1;q11.2). Additional genetic changes occur in less than 10 % of
CML cases at the time of diagnosis and other genetic changes are seen in 60–80 % of the cases in advanced
disease. Even though deletions in chromosome 9 are not rare findings in advanced phase-CML, del(9)(p23p11.1) as
sole additional abnormality detected by fluorescence in situ hybridization (FISH) technique, to our knowledge has
not been described in the literature.
Results: A complete cytogenetic and molecular cytogenetic analysis, molecular biology method (reverse
transcription polymerase chain reaction (RT-PCR)), and immunophenotype confirmed to be a CML case in blast
crisis (BC). It revealed del(9)(p23p11.1) as sole abnormality detected by FISH technique besides Ph chromosome,
which leads to monoallely of tumor suppressor gene CDKN2A (cyclin-dependent kinase inhibitor 2A) before
Imatinib mesylate (IM) treatment.
Conclusions: The patient did not demonstrate a good response to IM treatment. The underlying mechanisms and
prognostic implications of these cytogenetic abnormalities are discussed.
Keywords: Chronic myeloid leukemia, Philadelphia chromosome, del(9)(p24p12), CDKN2A gene, Prognostic factorsBackground
Chronic myeloid leukemia (CML) is a myeloproliferative
disorder. It is mainly characterized by the presence of a
derivative chromosome 22 [der(22)], the so-called Phila-
delphia chromosome (Ph), which is due to a reciprocal
translocation t(9;22)(q34.1;q11.2). This rearrangement
involves the breakpoint cluster region (BCR) gene
22q11.2 and the c-Abelson (ABL1) gene 9q34, resulting
in the BCR-ABL1 fusion gene, encoding a constitutively
active tyrosine kinase protein [1].
The Ph chromosome can be observed as a sole
chromosomal anomaly during the early chronic phase
(CP) of CML (in more than 90 % of the CML cases),
additional genetic changes occur in less than 10 % of
cases at the time of diagnosis and other genetic changes* Correspondence: ascientific@aec.org.sy
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creativecommons.org/publicdomain/zero/1.0/are seen in 60–80 % of the cases in advanced disease [1].
The identification of this abnormality is important for
the diagnosis of the disease determined by the WHO
Tumor Classification [2] and for treatment purposes.
The first therapeutic choice, tyrosine kinas inhibitors,
has shown great therapeutic efficacy [3]. Imatinib mesy-
late (IM =Glivec, formerly STI571) is a chemically de-
signed drug able to block BCR/ABL1 tyrosine kinase
activity and is successfully used in CML patients [4].
Here we presented a de novo untreated Ph-positive
CML case in BC phase with del(9)(p23p11.1) as sole add-
itional abnormality detected by FISH technique, which
leads to monoallely of tumor suppressor gene CDKN2A
(cyclin-dependent kinase inhibitor 2A). This patient did
not demonstrate a good response to IM treatment.
Case presentation
In October 2013 a 40-year-old male was diagnosed as
suffering from CML. Physical examination revealed thecle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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weight, fever, anemia, and thrombocytopenia. Routine
peripheral blood test showed elevated white blood cells
(WBC) of 243.1 × 109/l (41 % of cells were blasts), red
blood cell (RBC) count was 3.62 × 106/mm3, hemoglobin
level was 6.8 g/dl and the platelet count 26 × 109/l.
Serum lactate dehydrogenase value (LDH) was 1,543 U/l
(normal level <460 U/l). The patient was diagnosed as
CML-BC according to WHO recommendations, in a
high Sokal risk of 29.7 (0.8–1.2), high Hasford (Euro)
risk of 2,856 (>1,480), low Eutos risk of 40 (<87) and
Etous probability of no complete cytogenetic response
(CCgR) at 18 months was 15 %. In fact, the patient started
on IM treatment (400 mg/day) for overall 1 month; then
he increased IM daily dose to 800 mg for 1 month but the
treatment was not successful and the patient had a tooth-
ache, anemia, and thrombocytopenia. Later he was given
IM 400 mg daily dose for 2 months. Under the latter ther-
apy the previous reported relevant symptoms disappeared.
Unfortunately the patient died 7 months after diagno-
sis from the disease under the treatment for unknown
reason.
Results
Prior to the IM-treatment GTG-banding revealed a
karyotype of 46,XY,t(9;22)[11]/ 46,XY,t(9;22),del(9)(p?)[9]Fig. 1 GTG-banding revealed a deletion of the short arm of a derivativ
by arrowhead(Fig. 1). Further molecular cytogenetics studies were
performed (Fig. 2). Dual-color-fluorescence in situ
hybridization (FISH) prior to IM-treatment using a
specific probe for BCR and ABL1 revealed two fusion
signals, on the der(9) and der(22), respectively (Fig. 2a).
A probe-set specific for subtelomeric (ST) regions in 9p
and 9q revealed one green and one red signal on der(9),
and one green, and one red signal on the der(9) and
der(22), respectively (Fig. 2b). Chromosome 9 was studied
with whole chromosome painting (WCP) probe and did
not provide any hint on cryptic translocations (data not
shown). A probe specific for CDKN2A confirmed that the
deletion visible in the short arm encompassed subband
9p21 (Fig. 2c). Multicolor banding (MCB) using a specific
probe for chromosome 9 confirmed a terminal deletion of
9p23 to 9p11.1 (Fig. 2d). RT-PCR pre IM treatment con-
firmed the presence of the BCR-ABL1 fusion (b2a2 tran-
script) revealing a major M-BCR transcript, most often
identified in CML (data not shown). Thus, the following
final karyotype prior IM-treatment was determined:
46,XY,t(9;22)(q34;q11.2)[11]/46,XY,der(9)(9pter- > 9p
23::9p11.1- > 9q34::22q11.2- > 22qter),der(22)t(9;22)(q34;
q11.2)[9].
The abnormal cell population (~42-45 % blasts in per-
ipheral blood specimen) showed the following immuno-
phenotype, which was consistent with CML-BC (WHOe chromosome 9 del(9)(p?). A derivative chromosome is marker
Fig. 2 Karyotype and chromosomal aberrations were confirmed using molecular cytogenetic approaches. a FISH using probes for BCR (green)
and ABL (red) showed 2 copies of BCR/ABL on Ph chromosome and on der(9), respectively. b FISH using probes for ST 9p (green) and ST 9q (red)
showed; 1 green and 1 red signal on der(9); and 1 red signal on Ph chromosome and 1 green signal on der(9). c The deletion of CDKN2A was
identified on the der(9). d The application of MCB 9 characterized the del(9)(p24p12) comprehensively. Abbreviations: # = chromosome;
der = derivative chromosome
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,CD22+, CD10+, CD41a+, CD34−, HLADr−, CD5−, CD7-,
CD2−, CD209−, CD11c−, CD79b−, sIgM−, sIgD−, CD103−,
CD138−, CD56−, CD57− and expressed CD64, CD38, and
CD4 heterogeneously.
Conclusions
We described a de novo untreated CML case in BC with
del(9)(p23p11.1) as sole additional acquired abnormality,
which leads to monoallely of tumor suppressor gene
CDKN2A as located at 9p21. Up to date, there are 7
CML cases listed in Mitelman Database showed the in-
volvement of the short arm of chromosome 9, two of
them revealed involvement of 9p21 [5]. Also, loss of a
part of the short arm of chromosome 9 (p12 and/or
p21) in CML-BC are reviewed in two previous studies
[5, 6]. To the best of our knowledge, this chromosomal
abnormality del(9)(p23p11.1) has not been previously
observed in CML [7].
According to the literature, approximately 10 % of
CML patients present in advanced phases called acceler-
ated phase (CML-AP) or CML-BC, without a clinically
evident CP [8]. Even with the advent of tyrosine kinaseinhibitor (TKI) therapy, the phase of disease remains an
important prognostic factor in CML [9, 10].
The progression to advanced phases of disease is
caused by the development of genetic lesions in
addition to BCR-ABL1 translocation; secondary cyto-
genetic changes are identified in more than 80 % of pa-
tients by the time of progression to CML-BC [11].
Even in the absence of other features of CML-AP or
CML-BC, the acquisition of new cytogenetic abnor-
malities in patients treated with IM is associated with
loss of response and poor prognosis [12, 13].
The t(9;22) or a variant Ph are frequently the sole
chromosomal anomaly during the CP [1]. The most com-
mon secondary chromosomal aberrations in advanced
phase CML are +8, +Ph, i(17q), +19, −Y, +21, +17, −7,
and −17 [1].
The median time to progression from CML-CP to
CML-BC is 3–5 years in untreated patients or in pa-
tients treated with hydroxyurea [14]. However, BC is
typically preceded by an intermediate AP of disease by a
period of 4–6 months [15], but up to 25 % of CML-BC
cases develop without any clinically evident preceding
AP [16].
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sion are complex and are likely related to genetic in-
stability and impaired DNA repair mechanisms that
are consequences of BCR-ABL1 activity [17–19]. In
addition to cytogenetic aberrations, BCR-ABL1 ampli-
fication, gene mutations, and epigenetic changes such
as gene methylation also appear to play a role in dis-
ease progression [20]. Interestingly, different BC phe-
notypes have been associated with unique patterns of
molecular evolution: ABL kinase domain mutations
that confer resistance to TKIs occur frequently in
lymphoid BC, while myeloid BC is more commonly as-
sociated with cytogenetic evolution. BCR-ABL1 ampli-
fication is seen in about 31 % of both myeloid and
lymphoid BC cases [21].
CDKN2A and CDKN2B are tumor suppressor genes
located in 9p21. They belong to the family of inhibitors
of cyclin-dependent kinases. The CDKN2A gene encodes
two proteins, p14ARF and p16INK4a, and the CDKN2B
gene p15 INK4b protein, which as key regulators of G1
phase cell-cycle arrest and senescence [22]. These genes
product is inactivated in a wide range of human cancers
through epigenetic mechanisms [22, 23],
Deletion at 9p21 is especially frequent in acute
lymphocytic leukemia (ALL), occurring at more than of
20 % in B-cell precursor ALL and approximately
50 % T-ALL patients [24]. The 9p21 deletions have been
suggested to be associated with unfavorable outcome in
both adult ALL and pediatric ALL, although the prog-
nostic impact of CDKN2A deletions in pediatric ALL ap-
pears controversial [24–27].
Recently, FOXA1 is a key transcription (TF) factor for
CDKN2A expression [23, 28]. FOXA1 is a member of
forkhead family TFs with remarkable pioneering activity
to open closed chromatin for its subsequent cooperation
with other master TF in embryogenesis and organ devel-
opment [29, 30].
In conclusion, we described de novo untreated CML
case in BC with del(9)(p23p11.1) as sole additional ac-
quired abnormality detected by FISH technique, which
leads to monoallely of tumor suppressor gene CDKN2A
as located at 9p21. The patient did not demonstrate a
good response to Imatinib treatment.Materials and Methods
Chromosome analysis
Chromosome analysis applying GTG-banding accord-
ing to standard procedures [31] was performed prior
IM treatment. 20 metaphase cells derived from un-
stimulated bone marrow culture were analyzed. Kar-
yotypes were described according to the International
System for Human Cytogenetic Nomenclature (ISCN
2009).Molecular cytogenetics
Fluorescence in situ hybridization (FISH) using the LSI
BCR/ABL dual color dual fusion translocation probe
(Abbott Molecular/Vysis, Des Plaines, IL, USA), a locus
specific probe for CDKN2A gene (LSI p16 in 9p21) with
a probe for centromere nine, and a subtelomeric probe
for 9p and 9q (Abbott Molecular/Vysis, Abbott Park, IL,
USA) were applied together with whole chromosome
painting (WCP) probe for chromosome 9 (MetaSystems,
Altlussheim, Germany) according to manufacturer’s in-
structions [31]. Also a multicolor banding probe (MCB)
sets based on microdissection derived region-specific li-
braries for chromosome 9 was applied as previously de-
scribed [32]. A minimum of ten metaphase spreads was
analyzed, using a fluorescence microscope (AxioIma-
ger.Z1 mot, Carl Zeiss Ltd., Hertfordshir, UK) equipped
with appropriate filter sets to discriminate between a
maximum of five fluorochromes plus the counterstain
DAPI (4',6- diamino-2-phenylindole). Image capture and
processing were performed using an ISIS imaging system
(MetaSystems, Altlussheim, Germany).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
and for BCR/ABL1 fusion transcripts
Total RNA extracted from peripheral blood sample
using the InviTrap RNA kit (Invitek, Berlin, Germany)
according to the manufacturer’s recommendations. cDNA
was prepared from 5 μg of total RNA with the Genequal-
ity BCR-ABL1 kit (AB Analitica, Padova, Italy) and BCR-
ABL1 fusion transcript was performed according to the
manufacturer’s instructions (AB Analitica, Padova, Italy).
Flow cytometric immunophenotype
Flow cytometry of leukemic blasts was performed using
a general panel of fluorescent antibodies against the fol-
lowing antigens typical for different cell lineages and cell
types: CD1a, CD2, CD3, CD4, CD5, CD8, CD10, CD11b,
CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD22,
CD23, CD32, CD33, CD34, CD38, CD41a, CD45, CD56,
CD57, CD64, CD103, CD117, CD123, CD209, CD235a
and CD243; in addition antibodies against Kappa and
Lambda light Chains, sIgD, sIgM, and HLADr were ap-
plied (BD Biosciences). Four-color immunophenotyping
on peripheral blood specimen was performed. Samples
were stained and analyzed on a BD FACSCalibur™ flow
cytometer according to BD Biosciences manuals and
products insert sheets. Autofluorescence, viability, and
isotype controls were included. Flow cytometric data ac-
quisition and analysis were conducted by BD Cellquest™
Pro software.
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